case ventilatory depression returns. The use of a larger dose of naloxone, given either intravenously or intramuscularly, is being investigated to determine whether the action of naloxone can be usefully prolonged.
4Evans, J M, Hogg, M I J, and Rosen, M, British J'ournal of Anaesthesia, in press. 5 Siegel, S, Non-parametric Statistics, (International Student Edition).
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Summary
In a multicentre trial ofstreptokinase in acute myocardial infarction 302 patients received an intravenous infusion of 2 500 000 IU of streptokinase over 24 hours, while 293 patients served as controls. Neither group received anticoagulants unless indicated by thromboembolic complications. No significant difference in mortality was evident during inpatient treatment nor at six-week or six-month follow-up. The inpatient death rate was 12 60% in the streptokinase group and 1377% among controls.
There was no significant difference in the peak levels or pattern of enzyme increase. The incidence of cardiac failure and reinfarction was similar in the two groups, but major arrhythmias were less common in those on streptokinase (P <0 05). In the streptokinase group there were 36 minor and six more serious haemorrhagic com-Introduction Since the introduction of streptokinase into clinical practice 17 years ago' 2 the therapeutic value of thrombolytic agents in acute myocardial infarction has remained in doubt. Only recently have a series of major controlled trials been undertaken (table I) .3-7No conclusive result in favour of streptokinase has emerged from these studies, in which the initial thrombolytic treatment followed by anticoagulation was compared with anticoagulant treatment alone. The trial reported here was started in the United Kingdom in August 1971 and ended in June 1974. Its object was to determine whether thrombolytic treatment influenced early or late mortality, the incidence of complications, and the pathological findings in the hearts of patients who died. Preliminary results have been briefly reported8; we present here the final results, concluding the study at six months' follow-up.
Design of trial
Criteria for admission-The trial was conducted in coronary care units in five different hospitals, the only requisite for entry being a diagnosis of myocardial infarction within the previous 24 hours. At the time of entry into the trial this rested necessarily on the clinical picture and the initial electrocardiogram (ECG). The ECG criteria for infarction used were those of the World Health Organisation,9 the diagnosis of acute infarction was not accepted unless there was a significant increase in either serum aspartate aminotransferase (SGOT) or lactate dehydrogenase (LDH) concentrations, or both. Both sexes were accepted and no upper age limit was prescribed.
Statistical design-The statistical design, described by Armitage, '0 tested the null hypothesis that the death rates in the streptokinase and control groups were the same against a two-sided alternative and at 4, 24, and 48 hours. The FDP of all patients was measured in a single laboratory at one of the centres (JEM). Necropsies were performed whenever possible in patients dying in hospital. The hearts were preserved with minimal dissection for later examination by the pathologist to the trial (CLB).
Follow-up-Patients were reassessed by means of clinical examination, chest x-ray examination, and ECG six weeks and six months after infarction.
Results
Sixty-one of the 600 patients admitted to the trial were excluded from the analysis because of failure to show recent myocardial infarction; four others were excluded because they departed from the protocol. There was no relationship between mortality and site of infarction (table VIII) .
Incidence of cardiac failure, reinfarction, and arrhythmias-Cardiac failure was diagnosed on conventional clinical grounds, while the same diagnostic criteria were applied to reinfarction as were used for the original infarct.9 ECG tracings were used to define the nature and incidence of arrhythmias and other disorders of conduction. We thought that in the interest of brevity these could be grouped under a single heading of "major" arrhythmias, which included atrial fibrillation, supraventricular tachycardia, left or right bundle-branch block, heart block (grades 1, 2, and 3), ventricular tachycardia, and fibrillation and asystole. The incidences of cardiac failure, reinfarction, and major arrhythmias is shown in table IX. The control group showed a significantly greater incidence of major arrhythmias.
Enzyme levels-The enzyme peaks were of comparable magnitude and occurred at much the same interval after infarction in both groups (tables X and XI). SGOT levels were measured only during the first 24 hours after admission to the study, while LDH was estimated daily for 10 days. As expected the peak levels were significantly higher in those patients who died. Fever-Inspection of the patients' temperature records showed no significant difference in pattern between the two groups. Febrile reactions attributed to streptokinase were few, but 13 patients were given corticosteroids, and five of these showed fever disproportionate to the infarct. Steroids were also given to six patients in the control group for conditions unrelated to the infarction.
Fibrinolytic activity-As a measure of the effectiveness of streptokinase treatment fibrinolytic activity was assessed by measuring the level of FDP in the serum by the tanned red cell haemagglutinationinhibition immunoassay.12 The FDP levels at four hours in the treated and control groups are given in Thromboembolic complications-Clinically diagnosed venous thrombosis, pulmonary embolism, and systemic embolism occurred more often in the control group. The incidence of stroke was similar in both groups (table XV) .
Pathology-Fifty-three hearts were available for pathological examination, 27 from the streptokinase group and 26 from the control group. Two hearts from the streptokinase group were excluded from the study when it was found that no streptokinase had been administered before death, and two control hearts were excluded because of The desired thrombin time range is two to four times the control value (admission).
As expected thrombin times at four hours were not raised in the controls. Haemorrhage in plaque 3 6 Stenosis only 3 3 Previous occlusion 8 6 Endocardial thrombus... 11 10 Myocardial tears 5 4
Evidence of previous ischaemia 11 12 Extension of infarct 2 3 Haemorrhagic infarcts... 
Discussion
The rationale of streptokinase treatment in acute myocardial infarction has never rested on the sanguine expectation that lysis of newly formed thrombus would protect the threatened myocardium from necrosis. It seemed possible, however, that the size of the infarct might be reduced by preventing extending thrombosis in the affected or neighbouring arteries or in small vessels at the periphery of the infarct. If this were so a fall in mortality or in early complications might be apparent. The results of our own and other studies conducted entirely in coronary care units have failed to confirm this hypothesis, however. Details of the earlier major trials of streptokinase in acute infarction are summarised in table I together with those of our study. The dose and duration of streptokinase treatment are broadly comparable and in all trials the treatment was started within 24 hours of the onset of symptoms. Like ours, patients in the Italian and Australian studies were all treated in coronary care units. Our trial differed chiefly in that anticoagulant treatment was given to neither those receiving streptokinase nor controls unless indicated by the development of thromboembolic complications.
On the basis of the simple prognostic index only nine patients fell into subgroup C. Admission of patients to the trial at the five participating centres was neither universal nor consecutive but was governed by administrative and staffing considerations. There were understandable problems in entering a patient whose clinical condition was already absorbing the efforts of the staff in supportive or resuscitative measures. The small number of patients in this group precludes meaningful analysis and leaves open the question whether such patients might benefit from streptokinase. Once admitted to the trial, however, allocation of the patient to either the streptokinase or control group was according to strict blind random chart.
No significant difference in overall mortality emerges from analysis of prognostic subgroups A and B, but there was a wide and unexplained variation between the mortality rates at different centres (table VI) . This has also been seen in other studies.5 Two patients in the streptokinase and three in the control group died within six hours of infarction.
The largest difference in the hospital death rates between those on streptokinase and controls occurred 12-24 hours after infarction. Though fibrinolytic activity should be maximal at this time the difference was still not significant (P=007), and there are no data to suggest that this slightly favourable trend would have continued had anticoagulants been used after the streptokinase infusion. The analysis shows no evidence that any particular feature such as age, early treatment, or site of infarct influenced the outcome in the two groups. Nor does a comparison of the peak values of SGOT or LDH suggest that streptokinase limits the extent of myocardial necrosis. It was not unexpected that the mean peaks in the 85 patients who died exceeded those of the survivors, for it is now established that the magnitude of the enzyme rise reflects the size of the infarct.
The incidence of cardiac failure and reinfarction in hospital was similar in the two groups. Although the incidence of major arrhythmias was less in the streptokinase group this had no bearing on the ultimate mortality.
Though the incidence of haemorrhagic manifestations in the streptokinase group cannot be ignored it was not prohibitive, being a possible contributory cause of death in only one patient. Allergic reactions to streptokinase did not constitute a problem despite the absence of routine corticosteroid cover. The difference in thromboembolic complications in the two groups was favourable to streptokinase and may reasonably be attributed to the drug's thrombolytic action at a time when immobility and reduced cardiac output were conducive to stasis.
Pathological examination of hearts showed that the only difference between the groups that might be significant was the finding of haemorrhagic infarcts in three patients given streptokinase, a change that has been commented on.'4 The rather high incidence of myocardial rupture in both groups was probably related to external cardiac massage during attempted resuscitation.
Our trial, like the Italian and Australian ones, has failed to provide support for the routine use of streptokinase in acute myocardial infarction. Its prophylactic value in crescendo angina has yet to be assessed by a controlled study.
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